🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Jecho Biopharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Jecho Biopharmaceuticals as lead sponsor. Synced 26 Sep 2026
5Current trials
5Recruiting now
1Drug in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Jecho Biopharmaceuticals is the lead sponsor of 5 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are JL19001. The most-studied condition is Advanced Solid Tumor (Phase 1).

ClinicalTrials.gov trials by status

  • Recruiting5100%

Trials by phase

  • Phase 1360%
  • Phase 1/2240%
01

Clinical trials sponsored by Jecho Biopharmaceuticals

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase I Study of JLM019 Injection
NCT07623850 · ClinicalTrials.gov ↗ · Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Phase 1 Recruiting 2026-01 China
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT07603479 · ClinicalTrials.gov ↗ · Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma)
Drug: JL19001
Phase 1 Recruiting 2026-06 China
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
NCT07501559 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma Multiforme(GBM)
Phase 1/2 Recruiting 2026-06 China
A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.
NCT07483970 · ClinicalTrials.gov ↗ · High Risk Non-muscle Invasive Bladder Cancer
Drug: JL19001
Phase 1 Recruiting 2026-05 China
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders
NCT07579741 · ClinicalTrials.gov ↗ · HIV Infections
Phase 1/2 Recruiting 2026-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Jecho Biopharmaceuticals trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Jecho Biopharmaceuticals trials

10 conditions
Advanced Solid Tumor (Phase 1)1Hodgkin Lymphoma1Non-Hodgkin Lymphoma1Malignancies1Solid Malignant Tumor1NHL (Non-Hodgkin Lymphoma)1Solid Tumor Cancer1Recurrent Glioblastoma Multiforme(GBM)1High Risk Non-muscle Invasive Bladder Cancer1HIV Infections1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China55

A trial with sites in more than one country appears in each of those registers.

05

Questions about Jecho Biopharmaceuticals trials

How many clinical trials does Jecho Biopharmaceuticals sponsor?

Jecho Biopharmaceuticals is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Jecho Biopharmaceuticals trials recruiting?

Yes. 5 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jecho Biopharmaceuticals testing?

Its current trials name 1 drug or biological as interventions. The most frequent are JL19001 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.